Home › Trial NCT00819780
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
- Trial IDNCT00819780
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorAmgen
- Enrollment285
- Start date2009-04-24
- ConditionsColon Cancer · Colorectal Cancer · Rectal Cancer · Metastatic Colorectal Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.